Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 460

1.

Beta-blocker therapy and risk of vascular dementia: A population-based prospective study.

Holm H, Ricci F, Di Martino G, Bachus E, Nilsson ED, Ballerini P, Melander O, Hansson O, Nägga K, Magnusson M, Fedorowski A.

Vascul Pharmacol. 2020 Jan 17:106649. doi: 10.1016/j.vph.2020.106649. [Epub ahead of print]

PMID:
31958512
2.

Functional brain architecture is associated with the rate of tau accumulation in Alzheimer's disease.

Franzmeier N, Neitzel J, Rubinski A, Smith R, Strandberg O, Ossenkoppele R, Hansson O, Ewers M; Alzheimer’s Disease Neuroimaging Initiative (ADNI).

Nat Commun. 2020 Jan 17;11(1):347. doi: 10.1038/s41467-019-14159-1.

3.

Autocatalytic amplification of Alzheimer-associated Aβ42 peptide aggregation in human cerebrospinal fluid.

Frankel R, Törnquist M, Meisl G, Hansson O, Andreasson U, Zetterberg H, Blennow K, Frohm B, Cedervall T, Knowles TPJ, Leiding T, Linse S.

Commun Biol. 2019 Oct 8;2(1):365. doi: 10.1038/s42003-019-0612-2.

PMID:
31925210
4.
5.

[18F]Flortaucipir distinguishes Alzheimer's disease from progressive supranuclear palsy pathology in a mixed-pathology case.

Smith R, Pawlik D, Nilsson CF, Englund E, Hansson O.

Acta Neuropathol. 2020 Jan 4. doi: 10.1007/s00401-019-02121-w. [Epub ahead of print] No abstract available.

PMID:
31903496
6.

Cognitively normal women with Alzheimer's disease proteinopathy show relative preservation of memory but not of hippocampal volume.

Caldwell JZK, Cummings JL, Banks SJ, Palmqvist S, Hansson O.

Alzheimers Res Ther. 2019 Dec 26;11(1):109. doi: 10.1186/s13195-019-0565-1.

7.

Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders.

Hall S, Janelidze S, Zetterberg H, Brix B, Mattsson N, Surova Y, Blennow K, Hansson O.

Mov Disord. 2019 Dec 13. doi: 10.1002/mds.27950. [Epub ahead of print]

PMID:
31837067
8.

Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays.

Blennow K, Shaw LM, Stomrud E, Mattsson N, Toledo JB, Buck K, Wahl S, Eichenlaub U, Lifke V, Simon M, Trojanowski JQ, Hansson O.

Sci Rep. 2019 Dec 13;9(1):19024. doi: 10.1038/s41598-019-54204-z.

9.

Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology.

Blennow K, Chen C, Cicognola C, Wildsmith KR, Manser PT, Bohorquez SMS, Zhang Z, Xie B, Peng J, Hansson O, Kvartsberg H, Portelius E, Zetterberg H, Lashley T, Brinkmalm G, Kerchner GA, Weimer RM, Ye K, Höglund K.

Brain. 2019 Dec 13. pii: awz346. doi: 10.1093/brain/awz346. [Epub ahead of print]

PMID:
31834365
10.

Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity.

Pereira JB, Ossenkoppele R, Palmqvist S, Strandberg TO, Smith R, Westman E, Hansson O.

Elife. 2019 Dec 9;8. pii: e50830. doi: 10.7554/eLife.50830.

11.

The TCF7L2-dependent high-voltage activated calcium channel subunit α2δ-1 controls calcium signaling in rodent pancreatic beta-cells.

Ye Y, Barghouth M, Luan C, Kazim A, Zhou Y, Eliasson L, Zhang E, Hansson O, Thevenin T, Renström E.

Mol Cell Endocrinol. 2020 Feb 15;502:110673. doi: 10.1016/j.mce.2019.110673. Epub 2019 Dec 2.

PMID:
31805307
12.

Apathy and anxiety are early markers of Alzheimer's disease.

Johansson M, Stomrud E, Lindberg O, Westman E, Johansson PM, van Westen D, Mattsson N, Hansson O.

Neurobiol Aging. 2020 Jan;85:74-82. doi: 10.1016/j.neurobiolaging.2019.10.008. Epub 2019 Oct 19.

PMID:
31735378
13.

Midlife Atherosclerosis and Development of Alzheimer or Vascular Dementia.

Gustavsson AM, van Westen D, Stomrud E, Engström G, Nägga K, Hansson O.

Ann Neurol. 2020 Jan;87(1):52-62. doi: 10.1002/ana.25645. Epub 2019 Nov 27.

PMID:
31721283
14.

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease.

Palmqvist S, Insel PS, Stomrud E, Janelidze S, Zetterberg H, Brix B, Eichenlaub U, Dage JL, Chai X, Blennow K, Mattsson N, Hansson O.

EMBO Mol Med. 2019 Dec;11(12):e11170. doi: 10.15252/emmm.201911170. Epub 2019 Nov 11.

15.

Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer's disease.

Whelan CD, Mattsson N, Nagle MW, Vijayaraghavan S, Hyde C, Janelidze S, Stomrud E, Lee J, Fitz L, Samad TA, Ramaswamy G, Margolin RA, Malarstig A, Hansson O.

Acta Neuropathol Commun. 2019 Nov 6;7(1):169. doi: 10.1186/s40478-019-0795-2.

16.

Loss of ZnT8 function protects against diabetes by enhanced insulin secretion.

Dwivedi OP, Lehtovirta M, Hastoy B, Chandra V, Krentz NAJ, Kleiner S, Jain D, Richard AM, Abaitua F, Beer NL, Grotz A, Prasad RB, Hansson O, Ahlqvist E, Krus U, Artner I, Suoranta A, Gomez D, Baras A, Champon B, Payne AJ, Moralli D, Thomsen SK, Kramer P, Spiliotis I, Ramracheya R, Chabosseau P, Theodoulou A, Cheung R, van de Bunt M, Flannick J, Trombetta M, Bonora E, Wolheim CB, Sarelin L, Bonadonna RC, Rorsman P, Davies B, Brosnan J, McCarthy MI, Otonkoski T, Lagerstedt JO, Rutter GA, Gromada J, Gloyn AL, Tuomi T, Groop L.

Nat Genet. 2019 Nov;51(11):1596-1606. doi: 10.1038/s41588-019-0513-9. Epub 2019 Nov 1.

PMID:
31676859
17.

Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease.

Ossenkoppele R, Lyoo CH, Sudre CH, van Westen D, Cho H, Ryu YH, Choi JY, Smith R, Strandberg O, Palmqvist S, Westman E, Tsai R, Kramer J, Boxer AL, Gorno-Tempini ML, La Joie R, Miller BL, Rabinovici GD, Hansson O.

Alzheimers Dement. 2019 Oct 28. pii: S1552-5260(19)35375-0. doi: 10.1016/j.jalz.2019.08.201. [Epub ahead of print]

18.

Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration.

Höglund K, Schussler N, Kvartsberg H, Smailovic U, Brinkmalm G, Liman V, Becker B, Zetterberg H, Cedazo-Minguez A, Janelidze S, Lefevre IA, Eyquem S, Hansson O, Blennow K.

Neurobiol Dis. 2020 Feb;134:104645. doi: 10.1016/j.nbd.2019.104645. Epub 2019 Oct 25.

19.

A quick test of cognitive speed can predict development of dementia in Parkinson's disease.

Jalakas M, Palmqvist S, Hall S, Svärd D, Lindberg O, Pereira JB, van Westen D, Hansson O.

Sci Rep. 2019 Oct 28;9(1):15417. doi: 10.1038/s41598-019-51505-1.

20.

Midlife physical activity is associated with lower incidence of vascular dementia but not Alzheimer's disease.

Hansson O, Svensson M, Gustavsson AM, Andersson E, Yang Y, Nägga K, Hållmarker U, James S, Deierborg T.

Alzheimers Res Ther. 2019 Oct 20;11(1):87. doi: 10.1186/s13195-019-0538-4.

21.

Diffusion Tensor MRI to Distinguish Progressive Supranuclear Palsy from α-Synucleinopathies.

Spotorno N, Hall S, Irwin DJ, Rumetshofer T, Acosta-Cabronero J, Deik AF, Spindler MA, Lee EB, Trojanowski JQ, van Westen D, Nilsson M, Grossman M, Nestor PJ, McMillan CT, Hansson O.

Radiology. 2019 Dec;293(3):646-653. doi: 10.1148/radiol.2019190406. Epub 2019 Oct 15.

22.

Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948.

Smith R, Schöll M, Leuzy A, Jögi J, Ohlsson T, Strandberg O, Hansson O.

Eur J Nucl Med Mol Imaging. 2020 Feb;47(2):342-354. doi: 10.1007/s00259-019-04496-0. Epub 2019 Oct 14.

PMID:
31612245
23.

Autocatalytic amplification of Alzheimer-associated Aβ42 peptide aggregation in human cerebrospinal fluid.

Frankel R, Törnquist M, Meisl G, Hansson O, Andreasson U, Zetterberg H, Blennow K, Frohm B, Cedervall T, Knowles TPJ, Leiding T, Linse S.

Commun Biol. 2019 Oct 8;2:365. doi: 10.1038/s42003-019-0612-2. eCollection 2019.

24.

Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study.

van Maurik IS, Vos SJ, Bos I, Bouwman FH, Teunissen CE, Scheltens P, Barkhof F, Frolich L, Kornhuber J, Wiltfang J, Maier W, Peters O, Rüther E, Nobili F, Frisoni GB, Spiru L, Freund-Levi Y, Wallin AK, Hampel H, Soininen H, Tsolaki M, Verhey F, Kłoszewska I, Mecocci P, Vellas B, Lovestone S, Galluzzi S, Herukka SK, Santana I, Baldeiras I, de Mendonça A, Silva D, Chetelat G, Egret S, Palmqvist S, Hansson O, Visser PJ, Berkhof J, van der Flier WM; Alzheimer's Disease Neuroimaging Initiative.

Lancet Neurol. 2019 Nov;18(11):1034-1044. doi: 10.1016/S1474-4422(19)30283-2. Epub 2019 Sep 13.

PMID:
31526625
25.

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease.

Sjödin S, Brinkmalm G, Öhrfelt A, Parnetti L, Paciotti S, Hansson O, Hardy J, Blennow K, Zetterberg H, Brinkmalm A.

Alzheimers Res Ther. 2019 Sep 14;11(1):82. doi: 10.1186/s13195-019-0533-9.

26.

Increased functional connectivity of thalamic subdivisions in patients with Parkinson's disease.

Owens-Walton C, Jakabek D, Power BD, Walterfang M, Velakoulis D, van Westen D, Looi JCL, Shaw M, Hansson O.

PLoS One. 2019 Sep 4;14(9):e0222002. doi: 10.1371/journal.pone.0222002. eCollection 2019.

27.

Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter study.

Puschmann A, Jiménez-Ferrer I, Lundblad-Andersson E, Mårtensson E, Hansson O, Odin P, Widner H, Brolin K, Mzezewa R, Kristensen J, Soller M, Rödström EY, Ross OA, Toft M, Breedveld GJ, Bonifati V, Brodin L, Zettergren A, Sydow O, Linder J, Wirdefeldt K, Svenningsson P, Nissbrandt H, Belin AC, Forsgren L, Swanberg M.

Parkinsonism Relat Disord. 2019 Sep;66:158-165. doi: 10.1016/j.parkreldis.2019.07.032. Epub 2019 Jul 31.

28.

European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND).

Düzel E, Acosta-Cabronero J, Berron D, Biessels GJ, Björkman-Burtscher I, Bottlaender M, Bowtell R, Buchem MV, Cardenas-Blanco A, Boumezbeur F, Chan D, Clare S, Costagli M, de Rochefort L, Fillmer A, Gowland P, Hansson O, Hendrikse J, Kraff O, Ladd ME, Ronen I, Petersen E, Rowe JB, Siebner H, Stoecker T, Straub S, Tosetti M, Uludag K, Vignaud A, Zwanenburg J, Speck O.

Alzheimers Dement (Amst). 2019 Jul 31;11:538-549. doi: 10.1016/j.dadm.2019.04.010. eCollection 2019 Dec.

29.

β-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly.

Svenningsson AL, Stomrud E, Insel PS, Mattsson N, Palmqvist S, Hansson O.

Sci Rep. 2019 Aug 1;9(1):11180. doi: 10.1038/s41598-019-47638-y.

30.

Towards a unified protocol for handling of CSF before β-amyloid measurements.

Janelidze S, Stomrud E, Brix B, Hansson O.

Alzheimers Res Ther. 2019 Jul 19;11(1):63. doi: 10.1186/s13195-019-0517-9.

31.

Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography.

Mattsson N, Palmqvist S, Stomrud E, Vogel J, Hansson O.

JAMA Neurol. 2019 Jul 17. doi: 10.1001/jamaneurol.2019.2214. [Epub ahead of print]

PMID:
31314895
32.

Determining clinically meaningful decline in preclinical Alzheimer disease.

Insel PS, Weiner M, Mackin RS, Mormino E, Lim YY, Stomrud E, Palmqvist S, Masters CL, Maruff PT, Hansson O, Mattsson N.

Neurology. 2019 Jul 23;93(4):e322-e333. doi: 10.1212/WNL.0000000000007831. Epub 2019 Jul 9.

33.

α-synuclein-lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients.

Paslawski W, Zareba-Paslawska J, Zhang X, Hölzl K, Wadensten H, Shariatgorji M, Janelidze S, Hansson O, Forsgren L, Andrén PE, Svenningsson P.

Proc Natl Acad Sci U S A. 2019 Jul 23;116(30):15226-15235. doi: 10.1073/pnas.1821409116. Epub 2019 Jul 3.

34.

Primary fatty amides are potential plasma biomarkers for AD.

Mattsson N, Hansson O.

Nat Rev Neurol. 2019 Sep;15(9):498-499. doi: 10.1038/s41582-019-0229-6. No abstract available.

PMID:
31253949
35.

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status.

Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, Bittner T, Mattsson N, Eichenlaub U, Blennow K, Hansson O.

JAMA Neurol. 2019 Jun 24. doi: 10.1001/jamaneurol.2019.1632. [Epub ahead of print]

36.

A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies.

Perani D, Iaccarino L, Lammertsma AA, Windhorst AD, Edison P, Boellaard R, Hansson O, Nordberg A, Jacobs AH; IMBI Project.

Alzheimers Dement. 2019 Aug;15(8):1081-1103. doi: 10.1016/j.jalz.2019.02.004. Epub 2019 Jun 21.

PMID:
31230910
37.

Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer's disease.

Schultz N, Janelidze S, Byman E, Minthon L, Nägga K, Hansson O, Wennström M.

PLoS One. 2019 Jun 17;14(6):e0218561. doi: 10.1371/journal.pone.0218561. eCollection 2019.

38.

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.

Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE; and the NFL Group, Alvarez-Cermeño JC, Andreasson U, Axelsson M, Bäckström DC, Bartos A, Bjerke M, Blennow K, Boxer A, Brundin L, Burman J, Christensen T, Fialová L, Forsgren L, Frederiksen JL, Gisslén M, Gray E, Gunnarsson M, Hall S, Hansson O, Herbert MK, Jakobsson J, Jessen-Krut J, Janelidze S, Johannsson G, Jonsson M, Kappos L, Khademi M, Khalil M, Kuhle J, Landén M, Leinonen V, Logroscino G, Lu CH, Lycke J, Magdalinou NK, Malaspina A, Mattsson N, Meeter LH, Mehta SR, Modvig S, Olsson T, Paterson RW, Pérez-Santiago J, Piehl F, Pijnenburg YAL, Pyykkö OT, Ragnarsson O, Rojas JC, Romme Christensen J, Sandberg L, Scherling CS, Schott JM, Sellebjerg FT, Simone IL, Skillbäck T, Stilund M, Sundström P, Svenningsson A, Tortelli R, Tortorella C, Trentini A, Troiano M, Turner MR, van Swieten JC, Vågberg M, Verbeek MM, Villar LM, Visser PJ, Wallin A, Weiss A, Wikkelsø C, Wild EJ.

JAMA Neurol. 2019 Jun 17. doi: 10.1001/jamaneurol.2019.1534. [Epub ahead of print]

PMID:
31206160
39.

Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimer's Disease.

Minta K, Portelius E, Janelidze S, Hansson O, Zetterberg H, Blennow K, Andreasson U.

J Alzheimers Dis. 2019;69(4):1213-1220. doi: 10.3233/JAD-190187.

PMID:
31156172
40.

CSF placental growth factor - a novel candidate biomarker of frontotemporal dementia.

Hansson O, Santillo AF, Meeter LH, Nilsson K, Landqvist Waldö M, Nilsson C, Blennow K, van Swieten JC, Janelidze S.

Ann Clin Transl Neurol. 2019 Mar 29;6(5):863-872. doi: 10.1002/acn3.763. eCollection 2019 May.

41.

Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid.

Lifke V, Kollmorgen G, Manuilova E, Oelschlaegel T, Hillringhaus L, Widmann M, von Arnim CAF, Otto M, Christenson RH, Powers JL, Shaw LM, Hansson O, Doecke JD, Li QX, Teunissen C, Tumani H, Blennow K.

Clin Biochem. 2019 Oct;72:30-38. doi: 10.1016/j.clinbiochem.2019.05.005. Epub 2019 May 23.

42.

Method comparison study of the Elecsys® β-Amyloid (1-42) CSF assay versus comparator assays and LC-MS/MS.

Shaw LM, Hansson O, Manuilova E, Masters CL, Doecke JD, Li QX, Rutz S, Widmann M, Leinenbach A, Blennow K.

Clin Biochem. 2019 Oct;72:7-14. doi: 10.1016/j.clinbiochem.2019.05.006. Epub 2019 May 23.

43.

Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia.

Meeter LHH, Steketee RME, Salkovic D, Vos ME, Grossman M, McMillan CT, Irwin DJ, Boxer AL, Rojas JC, Olney NT, Karydas A, Miller BL, Pijnenburg YAL, Barkhof F, Sánchez-Valle R, Lladó A, Borrego-Ecija S, Diehl-Schmid J, Grimmer T, Goldhardt O, Santillo AF, Hansson O, Vestberg S, Borroni B, Padovani A, Galimberti D, Scarpini E, Rohrer JD, Woollacott IOC, Synofzik M, Wilke C, de Mendonca A, Vandenberghe R, Benussi L, Ghidoni R, Binetti G, Niessen WJ, Papma JM, Seelaar H, Jiskoot LC, de Jong FJ, Donker Kaat L, Del Campo M, Teunissen CE, Bron EE, Van den Berg E, Van Swieten JC.

J Neurol Neurosurg Psychiatry. 2019 Sep;90(9):997-1004. doi: 10.1136/jnnp-2018-319784. Epub 2019 May 23.

44.

Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression.

Pereira JB, Weintraub D, Chahine L, Aarsland D, Hansson O, Westman E.

NPJ Parkinsons Dis. 2019 May 3;5:7. doi: 10.1038/s41531-019-0079-3. eCollection 2019.

45.

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease.

Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P.

Alzheimers Res Ther. 2019 Apr 22;11(1):34. doi: 10.1186/s13195-019-0485-0. Review.

46.

Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism.

Sjöström H, Surova Y, Nilsson M, Granberg T, Westman E, van Westen D, Svenningsson P, Hansson O.

Sci Rep. 2019 Apr 15;9(1):6079. doi: 10.1038/s41598-019-42565-4.

47.

18F-Flortaucipir in TDP-43 associated frontotemporal dementia.

Smith R, Santillo AF, Waldö ML, Strandberg O, Berron D, Vestberg S, van Westen D, van Swieten J, Honer M, Hansson O.

Sci Rep. 2019 Apr 15;9(1):6082. doi: 10.1038/s41598-019-42625-9.

48.

CSF and blood biomarkers for Parkinson's disease.

Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, Mollenhauer B, Blennow K, Calabresi P.

Lancet Neurol. 2019 Jun;18(6):573-586. doi: 10.1016/S1474-4422(19)30024-9. Epub 2019 Apr 10. Review.

PMID:
30981640
49.

Corrigendum to: "Striatal changes in Parkinson disease: An investigation of morphology, functional connectivity and their relationship to clinical symptoms" [Psychiatry Research: Neuroimaging. Volume 275 (May 2018), Pages 5-13].

Owens-Walton C, Jakabek D, Li X, Wilkes FA, Walterfang M, Velakoulis D, van Westen D, Looi JCL, Hansson O.

Psychiatry Res Neuroimaging. 2019 Apr 30;286:76. doi: 10.1016/j.pscychresns.2019.03.013. No abstract available.

PMID:
30955528
50.

Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly.

Hahn A, Strandberg TO, Stomrud E, Nilsson M, van Westen D, Palmqvist S, Ossenkoppele R, Hansson O.

Cereb Cortex. 2019 May 1;29(5):2173-2182. doi: 10.1093/cercor/bhz020.

Supplemental Content

Loading ...
Support Center